Keywords
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

24591 Search results.

Relevance Rating New first Old first

NIHSS - NIH Stroke Scale

- 9/20/21 - 1 form, 1 itemgroup, 16 items, 9 languages
Itemgroup: NIHSS
https://en.wikipedia.org/wiki/National_Institutes_of_Health_Stroke_Scale

ICHOM Coronary Artery Disease - Peri-Inverventional Clinical Form

- 4/30/20 - 1 form, 8 itemgroups, 46 items, 1 language
Itemgroups: Administrative Data,Demographic factors,Baseline health status,Prior Treatments,TREATMENT VARIABLES,Acute complications of treatment,Major surgery complications,Major interventional cardiology complications
CORONARY ARTERY DISEASE DATA COLLECTION Version 2.0.3 Revised: April 5th, 2017 International Consortium for Health Outcomes Measurement (ICHOM), Source: http://www.ichom.org/ Notice: This work was conducted using resources from ICHOM, the International Consortium for Health Outcomes Measurement (www.ICHOM.org). The content is solely the responsibility of the authors and does not necessarily represent the official views of ICHOM. Conditions: Asymptomatic Coronary Artery Disease | Stable Angina | Acute Coronary Syndrome (Includes AMI) Treatment Approaches: Lifestyle Modification | Drug Therapy | Percutaneous Coronary Intervention (PCI) | Coronary Artery Bypass Grafting (CABG) This form contains peri-interventional clinical items. The items cover a timespan from prior to the intervention (e.g. PCI or CABG) until 30 days after it. They should be assessed at the entry event and at any new index event (e.g. new revascularization procedure or new diagnosis of ACS). Questionnaires used in this standard set: Rose Dyspnea Scale: The Rose Dyspnea Scale is free for all health care organizations, and a license is not needed. More information may be found at http://www.ahjonline.com/article/S0002-8703(09)00266-X/abstract Patient Health Questionnaire (PHQ-2): The PHQ-2 is free for all health care organizations, and a license is not needed. Copyright Pfizer, more Information on http://www.phqscreeners.com/ Seattle Angina Questionnaire (SAQ-7): Due to the need for a license for use of the SAQ-7 the actual questions of SAQ-7 will not be part of this version of the standard set. Publication: McNamara RL, Spatz ES, Kelley TA, et al. Standardized Outcome Measurement for Patients With Coronary Artery Disease: Consensus From the International Consortium for Health Outcomes Measurement (ICHOM). J Am Heart Assoc. 2015;4(5):e001767. Published 2015 May 19. doi:10.1161/JAHA.115.001767 For this version of the standard set, semantic annotation with UMLS CUIs has been added.

Stroke in French: Volet Accident Vasculaire Cérébral (AVC) - Risk factors (Facteurs de risque)

- 9/20/21 - 14 forms, 6 itemgroups, 21 items, 3 languages
Itemgroups: Hypertension,Diabetes,Lipid-lowering therapy,Tobacco use,Alcohol,Other
source: http://esante.gouv.fr/sites/default/files/asset/document/ci-sis_contenu_volet_avc_v2.1.0.pdf

Previous Therapy (Traitements en cours avant l'AVC)

2 itemgroups 4 items

Initial neurologic symptoms (Symptômes neurologiques initiaux)

1 itemgroup 13 items

Header

4 itemgroups 17 items

Notifiable Agents according to RKI - Erregerliste RKI

- 9/20/21 - 1 form, 1 itemgroup, 1 item, 2 languages
Itemgroup: Notifiable Agent
Notifiable Agents according to RKI. ODM created by Prof. Dr. Martin Dugas. Semantic annotation created by Prof. Dr. Sylvia Thun and Prof. Dr. Martin Digas

Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus Lab panels NCT00516321

- 9/20/21 - 1 form, 6 itemgroups, 71 items, 1 language
Itemgroups: Chemistry,Haematology,Liver Chemistry Assessments,Renal Laboratory Parameters,Urinalysis Dipstick,Other Laboratory Screenings
The purpose of this study is to assess the ability of eltrombopag to maintain a platelet count sufficient to facilitate initiation of antiviral therapy, to minimise antiviral therapy dose reductions and to avoid permanent discontinuation of antiviral therapy. The clinical benefit of eltrombopag will be measured by the proportion of subjects who are able to achieve a Sustained Virological Response (SVR). NCT00516321 https://clinicaltrials.gov/ct2/show/NCT00516321 Study Type: Interventional Study Design: Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2a Plus Ribavirin

Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus Lab Panels NCT00529568

- 9/20/21 - 1 form, 6 itemgroups, 72 items, 1 language
Itemgroups: Chemistry,Haematology,Liver Chemistry Assessments,Renal Laboratory Parameters,Urinalysis Dipstick,Other Laboratory Screenings
The purpose of this study is to assess the ability of eltrombopag to maintain a platelet count sufficient to facilitate initiation of antiviral therapy, to minimise antiviral therapy dose reductions and to avoid permanent discontinuation of antiviral therapy. The clinical benefit of eltrombopag will be measured by the proportion of subjects who are able to achieve a Sustained Virological Response (SVR). NCT00529568 https://clinicaltrials.gov/ct2/show/NCT00529568 Study Type: Interventional Study Design: Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Investigator) Primary Purpose: Treatment Official Title: Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2b Plus Ribavirin)

Safety and Efficacy of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus Infection Lab panels NCT00996216

- 9/20/21 - 1 form, 6 itemgroups, 49 items, 1 language
Itemgroups: Clinical Chemistry,Haematology,Liver Chemistry,Renal Assessments,Urinalysis Dipstick,Other Laboratory Screenings
The purpose of this study is to test the safety and tolerability of eltrombopag when used to increase and maintain platelet count. Platelet count to be maintained at a level sufficient to facilitate initiation of antiviral therapy, to minimize antiviral therapy dose reductions, and to avoid permanent discontinuation of antiviral therapy. NCT00996216 https://clinicaltrials.gov/ct2/show/NCT00996216 Study Type: Interventional Study Design: Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment Official Title: An Open-label, Multi-centre Rollover Study to Assess the Safety and Efficacy of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2a or Peginterferon Alfa-2b Plus Ribavirin)

ADT and Gekid shared uniform oncological basic data set - Uniform oncological basic data set

- 9/20/21 - 1 form, 19 itemgroups, 123 items, 2 languages
Itemgroups: Reason for report,Administrative Data,Reporting institution,Diagnosis,Histology,TNM Classification,Other classifications,Residual status,Distant metastases,Surgery,Complications,Radiotherapy,Radiotherapy Side effects,Systemic therapy,Systemic or expectant treatment,Systemic therapy side effects,Follow-Up,Tumor conference,Death
The uniform oncological basic data set of ADT and GEKID was adopted in March 2008 and updated in February, 2014. It applies to all types of cancer and is continuously supplemented by tumor-specific modules. By harmonizing Oncology base record, an instrument has been created which provides a harmonized oncological standard , prevents multiple documentaries and allows comparable acquisition and evaluation of cancer treatments in all clinical structures and federal states . Source: http://www.tumorzentren.de/onkol-basisdatensatz.html

Framingham Risk Score

- 9/20/21 - 1 form, 1 itemgroup, 7 items, 1 language
Itemgroup: Score items
The Framingham Risk Score is a sex-specific algorithm used to estimate the 10-year cardiovascular risk of an individual. The Framingham Risk Score was first developed based on data obtained from the Framingham Heart Study, to estimate the 10-year risk of developing coronary heart disease. In order to assess the 10-year cardiovascular disease risk, cerebrovascular events, peripheral artery disease and heart failure were subsequently added as disease outcomes for the 2008 Framingham Risk Score, on top of coronary heart disease. (http://en.wikipedia.org/wiki/Framingham_Risk_Score)

OPS Chapter 5 SURGERIES

- 9/20/21 - 1 form, 1 itemgroup, 1 item, 2 languages
Itemgroup: OPS 5
derived from: OPS - German Procedure Classification https://www.dimdi.de/static/en/klassi/ops/index.htm DIMDI publishes the OPS classification on behalf of the Federal Ministry of Health; it is in the public domain. Its use in inpatient care is laid down in 301 Volume V of the German Social Security Code (SGB V) and for surgical procedures in the outpatient sector in 295 SGB V.

Clinical Data epSOS Patient summary

- 9/20/21 - 1 form, 15 itemgroups, 54 items, 3 languages
Itemgroups: Allergy,Medical Alert Information,History of Past Illness,Social History,Pregnancy History,Vaccination,Medical Devices and Implants,Medical problems (current),Vital Signs Observations,Diagnostic Tests,Disability or function,Medication,Surgical Procedure,Treatments,Care plan
derived from http://www.epsos.eu/ and http://decor.nictiz.nl/art-decor/decor-datasets--epsos-

ACCF/AHA 2011 Key Data Elements and Definitions of a Base Cardiovascular Vocabulary for Electronic Health Records - Key Data Elements

- 6/25/21 - 1 form, 11 itemgroups, 110 items, 2 languages
Itemgroups: History and Physical Examination Elements,Patient History,Family History,Patient Assessment,Laboratory Results Elements,Diagnostic and Therapeutic Procedures Elements,Diagnostic Procedure Results,Therapeutic Procedures,Therapeutic Procedure Device Implants,Pharmacological Therapy Data Elements,Outcomes Data Elements
http://circ.ahajournals.org/content/124/1/103.full

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial